Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
NCT04616560Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in osteosarcoma (OS), Wilms' tumor and desmoplastic small round cell tumor (DSRCT), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose, Incidence of Adverse Events and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
osteosarcoma (OS)Wilms' tumordesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT04616560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616560.